Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Non-compliance with therapy may be associated with deterioration in the patient's condition, treatment failure, and increased use and cost of healthcare resources such as the requirement for additional drugs and hospital admission. Adherence to the prescribed regimen is affected by a number of variables including dosing interval, treatment duration, adverse effects, and palatability in pediatric patients. Accumulating evidence suggests that short-course antimicrobial therapy may be at least as effective as, and in some cases may be more effective than, traditional longer therapies (7-14 days) even in hospital-acquired pneumonia. Given the unique pharmacokinetic properties of azithromycin, attempts have been made to condense the traditional total dose over a 3-5-day period into single-dose therapy with the aim of improving treatment compliance. The results of two phase III CAP trials indicate that a single 2.0 g dose of azithromycin microspheres is a suitable alternative to 7 days of either clarithromycin XL or levofloxacin.
|Titolo:||Value of short-course antimicrobial therapy in community-acquired pneumonia|
|Autori interni:||BLASI, FRANCESCO BRUNO ARTURO (Primo)|
|Parole Chiave:||Azithromycin microspheres; Community-acquired pneumonia; Short-course therapy|
|Settore Scientifico Disciplinare:||Settore MED/10 - Malattie dell'Apparato Respiratorio|
|Data di pubblicazione:||2005|
|Appare nelle tipologie:||01 - Articolo su periodico|